Future medicinal chemistry · 2026
Novel multitargeted Imidazo[1,2-a]pyridine-1,3,4-oxadiazole hybrids: design, synthesis and biological evaluation as anti-Alzheimer's agents.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shah Drashti, Patel Ashish, Patel Alkesh
Аннотация
AIMS: To design, synthesize, and evaluate novel imidazo[1,2-a]pyridine derivatives as dual acetylcholinesterase (AChE) and β-secretase (BACE1) inhibitors for potential Alzheimer's disease (AD) therapy.
MATERIALS AND METHODS: A series of imidazo[1,2-a]pyridine derivatives (DS1-DS15) were synthesized via cyclization using various aryl and heteroaryl acids and characterized by MP, TLC, FTIR, MS, and 1H/13C NMR spectroscopy. Molecular docking studies were performed against AChE (PDB ID: 4EY7) and BACE1 (PDB ID: 4ACU). Pharmacokinetic properties were predicted using pkCSM, and molecular dynamics simulations were conducted for the lead compound. In vitro inhibitory activities were determined by IC50 values. In vivo anti-AD activity was evaluated in male Sprague Dawley rats using biochemical assays and histological analysis.
RESULTS: Compound DS7 showed the highest binding affinity toward both targets with stable protein-ligand interactions. It exhibited potent AChE inhibition (IC50 = 0.054 µM) and significant BACE1 inhibition (IC50 = 5.67 µM). In vivo studies demonstrated significant reversal of AD-associated biochemical and histopathological alterations at high dose.
CONCLUSION: DS7 emerged as a promising dual AChE/BACE1 inhibitor and a potential lead candidate for further optimization in AD drug development.
MATERIALS AND METHODS: A series of imidazo[1,2-a]pyridine derivatives (DS1-DS15) were synthesized via cyclization using various aryl and heteroaryl acids and characterized by MP, TLC, FTIR, MS, and 1H/13C NMR spectroscopy. Molecular docking studies were performed against AChE (PDB ID: 4EY7) and BACE1 (PDB ID: 4ACU). Pharmacokinetic properties were predicted using pkCSM, and molecular dynamics simulations were conducted for the lead compound. In vitro inhibitory activities were determined by IC50 values. In vivo anti-AD activity was evaluated in male Sprague Dawley rats using biochemical assays and histological analysis.
RESULTS: Compound DS7 showed the highest binding affinity toward both targets with stable protein-ligand interactions. It exhibited potent AChE inhibition (IC50 = 0.054 µM) and significant BACE1 inhibition (IC50 = 5.67 µM). In vivo studies demonstrated significant reversal of AD-associated biochemical and histopathological alterations at high dose.
CONCLUSION: DS7 emerged as a promising dual AChE/BACE1 inhibitor and a potential lead candidate for further optimization in AD drug development.